Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncotype DX-guided neoadjuvant endocrine therapy in postmenopausal breast cancer
jRCT1032230536Phase 2Recruiting
- Sponsor
- Exact Sciences
- Start
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Exact Sciences. Primary endpoints: Objective response rate by RECIST and Incidence of adverse events by CTCAE. Started Dec 2023; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1032230536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1032230536.